Editas Medicine, Inc. (EDIT) Return on equity 2016–2025
Editas Medicine, Inc. (EDIT) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-586.6%FY2025 · since FY2016: -72.2% → -586.6%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -586.6% | -410.0 pp |
| FY2024 | -176.6% | -132.7 pp |
| FY2023 | -43.9% | +17.2 pp |
| FY2022 | -61.1% | -26.3 pp |
| FY2021 | -34.8% | -5.3 pp |
| FY2020 | -29.5% | +21.5 pp |
| FY2019 | -51.0% | -4.4 pp |
| FY2018 | -46.6% | +11.3 pp |
| FY2017 | -57.8% | +14.4 pp |
| FY2016 | -72.2% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice